TopFunds

Merck & Co., Inc.

NYSE: MRK

Stock price

145.97 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1.6
2
0.9
2.3
3.8
2.8
5.1
5.7
0.1
6.7
7.3
16.7%
02Free cash flow per share
3.9
3.1
1.7
3.1
3.9
2.3
3.8
5.8
3.6
7.1
4.9
2.3%
03Dividends per share
1.7
1.8
1.8
1.9
2.2
2.4
2.6
2.8
3
3.1
3.3
6.6%
04Dividends payout, %
1.2%
1.3%
2.2%
83.2%
57.9%
87.9%
50.7%
48.3%
20.4%
45.8%
44.8%
44.2%
PROFIT AND LOSS STATEMENT
05Revenue
39,498
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
64,926
5.1%
06% Change
-
-
-
-
-
-
-
-
-
-
-
5.1%
07Cost of revenue
(14,934)
(14,030)
(12,912)
(13,509)
(12,016)
(13,618)
(13,626)
(17,411)
(16,126)
(15,193)
(18,195)
2%
08Gross profit
24,564
25,777
27,210
28,785
27,105
27,900
35,078
41,872
43,989
48,975
46,731
6.6%
09% Margin
62.2%
64.8%
67.8%
68.1%
69.3%
67.2%
72%
70.6%
73.2%
76.3%
72%
69.4% A
10Operating expenses
(17,017)
(20,278)
(20,413)
(19,854)
(19,179)
(22,352)
(21,879)
(23,590)
(41,035)
(28,754)
(23,245)
3.2%
11% of Revenue
(43.1)%
(50.9)%
(50.9)%
(46.9)%
(49)%
(53.8)%
(44.9)%
(39.8)%
(68.3)%
(44.8)%
(35.8)%
(48)% A
12Operating Income
7,547
5,499
6,797
8,931
7,926
5,548
13,199
18,282
2,954
20,221
23,486
12%
13Income tax expense
(942)
(718)
(4,103)
(2,508)
(1,565)
(1,340)
(1,521)
(1,918)
(1,512)
(2,803)
(2,804)
11.5%
14Net Income
4,442
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
15.2%
15% Margin
11.3%
9.9%
6%
14.7%
25.2%
17%
26.8%
24.5%
0.6%
26.7%
28.1%
17.3% A
16Shares Outstanding
2,841
2,787
2,748
2,679
2,580
2,541
2,538
2,542
2,547
2,541
2,507
(1.2)%
17EPS Basic
1.6
2.1
1
2.4
3.8
2.8
5.2
5.7
0.1
6.8
7.3
16.4%
18EPS Diluted
1.6
2
0.9
2.3
3.8
2.8
5.1
5.7
0.1
6.7
7.3
16.7%
19EBITDA
12,448
10,823
11,951
13,992
16,009
10,180
17,899
21,315
6,907
25,706
28,262
8.6%
% Margin
31.5%
27.2%
29.8%
33.1%
40.9%
24.5%
36.8%
36%
11.5%
40.1%
43.5%
32.3% A
20Net Interest Income (expense)
(383)
(365)
(369)
(429)
(619)
(772)
(770)
(805)
(781)
(856)
(1,014)
10.2%
21Net Debt / EBITDA
1.4
1.7
1.5
1.2
1.1
2.5
1.5
0.9
4.3
1
1.3
1.7 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
8,524
6,515
6,092
7,965
9,676
8,050
8,096
12,694
6,841
13,242
14,565
5.5%
23Short-term investments
4,903
7,826
2,406
899
774
-
-
498
252
447
-
-
24Accounts receivable
6,484
7,018
6,873
7,071
6,778
6,803
9,230
9,450
10,349
10,278
12,679
6.9%
25Other current assets
5,140
4,389
4,299
4,500
4,277
7,357
6,987
7,169
8,368
8,706
9,489
6.3%
26Inventory
4,700
4,866
5,096
5,440
5,978
5,554
5,953
5,911
6,358
6,109
6,658
3.5%
27Total Current Assets
29,751
30,614
24,766
25,875
27,483
27,764
30,266
35,722
32,168
38,782
43,516
3.9%
Non-Current Assets
28Net property, plant & equipment
12,507
12,026
12,439
13,291
15,053
17,000
19,279
21,422
23,051
23,779
26,823
7.9%
29Long-term investments
13,039
11,416
12,125
6,233
1,469
785
370
1,015
252
463
2,239
(16.2)%
30Other non-current assets
46,380
41,321
38,542
37,238
40,392
46,039
55,779
51,001
51,204
54,082
64,288
3.3%
31Total Non-Current Assets
71,926
64,763
63,106
56,762
56,914
63,824
75,428
73,438
74,507
78,324
93,350
2.6%
Total Assets
101,677
95,377
87,872
82,637
84,397
91,588
105,694
109,160
106,675
117,106
136,866
3%
LIABILITIES
Current Liabilities
32Accounts payable
2,533
2,807
3,102
3,318
3,738
4,327
4,609
4,264
3,922
4,079
4,404
5.7%
33Short-term debt
2,583
568
3,057
5,308
3,610
6,722
2,716
2,227
1,657
2,931
2,883
1.1%
34Other current liabilities
14,085
13,829
12,455
13,580
14,872
16,278
16,547
17,748
20,115
21,410
21,040
4.1%
35Total Current Liabilities
19,201
17,204
18,614
22,206
22,220
27,327
23,872
24,239
25,694
28,420
28,327
4%
Non-Current Liabilities
36Long-term debt
23,829
24,274
21,353
19,806
23,504
26,695
31,915
29,758
34,611
35,339
47,651
7.2%
37Other non-current liabilities
13,880
13,591
13,336
13,743
12,672
12,162
11,650
9,105
8,735
6,975
8,226
(5.1)%
38Total Non-Current Liabilities
37,709
37,865
34,689
33,549
36,176
38,857
43,565
38,863
43,346
42,314
55,877
4%
39Total Liabilities
56,910
55,069
53,303
55,755
58,396
66,184
67,437
63,102
69,040
70,734
84,204
4%
SHAREHOLDERS` EQUITY
40Common stock
1,788
1,788
1,788
1,788
1,788
1,788
1,788
1,788
1,788
1,788
1,788
-
41Retained earnings / (deficit)
45,348
44,133
41,350
42,579
46,602
47,362
53,696
61,081
53,895
63,069
73,075
4.9%
42Accumulated other comprehensive income / (loss)
(4,148)
(5,226)
(4,910)
(5,545)
(6,193)
(6,634)
(4,429)
(4,768)
(5,161)
(4,945)
(4,287)
0.3%
43Noncontrolling interests
91
220
233
181
94
87
73
67
54
59
56
(4.7)%
44Total shareholders' equity
44,767
40,308
34,569
26,882
26,001
25,404
38,257
46,058
37,635
46,372
52,662
1.6%
45Total Liabilities and shareholders' Equity
101,677
95,377
87,872
82,637
84,397
91,588
105,694
109,160
106,675
117,106
136,866
3%
46Total Debt
26,412
24,842
24,410
25,114
27,351
33,417
34,631
31,985
36,268
38,270
50,534
6.7%
47Net Debt
17,888
18,327
18,318
17,149
17,675
25,367
26,535
19,291
29,427
25,028
35,969
7.2%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
4,442
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
15.2%
49Depreciation & amortization
6,375
5,471
4,676
4,519
3,652
3,486
3,214
3,909
3,872
4,499
5,838
(0.9)%
50Share-based compensation expense
299
300
312
348
417
441
479
541
645
761
-
-
51Changes in working capital and other assets
1,305
685
(935)
(165)
(472)
(741)
(2,633)
126
8,124
(909)
(7,620)
-
52Net cash flows from operating activities
12,421
10,376
6,447
10,922
13,440
10,253
14,109
19,095
13,006
21,468
16,472
2.9%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(1,283)
(1,614)
(1,888)
(2,615)
(3,473)
(4,684)
(4,448)
(4,388)
(3,863)
(3,372)
(4,112)
12.4%
54Purchases of investments / marketable securities
(16,681)
(15,651)
(10,739)
(7,994)
(3,202)
(1,095)
(1)
(1,204)
(955)
(519)
(1,207)
(23.1)%
55Proceeds from maturities of marketable securities
20,413
14,353
15,664
15,252
8,622
2,812
1,026
721
1,658
377
1,678
(22.1)%
56Other investing activities
(7,207)
(298)
(358)
(329)
(4,576)
(6,476)
(13,132)
(89)
(10,923)
(4,220)
(10,100)
3.4%
57Net cash flows from investing activities
(4,758)
(3,210)
2,679
4,314
(2,629)
(9,443)
(16,555)
(4,960)
(14,083)
(7,734)
(13,741)
11.2%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(4,186)
(3,434)
(4,014)
(9,091)
(4,780)
(1,281)
(840)
384
(1,346)
(1,306)
(4,992)
1.8%
59Dividends paid, net
(5,117)
(5,124)
(5,167)
(5,172)
(5,695)
(6,215)
(6,610)
(7,012)
(7,445)
(7,840)
(8,176)
4.8%
60Debt issuance (repayments), net
3,492
(1,307)
(1,129)
837
1,248
5,011
1,631
(2,251)
4,184
2,309
11,377
12.5%
61Other financing activities
424
821
304
266
366
(347)
8,412
(240)
(203)
(195)
(131)
-
62Net cash flows from financing activities
(5,387)
(9,044)
(10,006)
(13,160)
(8,861)
(2,832)
2,593
(9,119)
(4,810)
(7,032)
(1,922)
(9.8)%
63Increase (decrease) in cash and cash equivalents
1,083
(2,009)
(423)
1,871
1,967
(1,769)
14
4,606
(5,864)
6,409
1,372
2.4%
64Cash and equivalents, ending balance
8,524
6,515
6,092
7,967
9,934
8,165
8,167
12,773
6,909
13,318
14,690
5.6%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
11,138
8,762
4,559
8,307
9,967
5,569
9,661
14,707
9,143
18,096
12,360
1.1%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Merck & Co., Inc. (MRK) financial statements and performance

Explore Merck & Co., Inc. (MRK) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.